BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27259245)

  • 1. A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer.
    Kinzel L; Ernst A; Orth M; Albrecht V; Hennel R; Brix N; Frey B; Gaipl US; Zuchtriegel G; Reichel CA; Blutke A; Schilling D; Multhoff G; Li M; Niyazi M; Friedl AA; Winssinger N; Belka C; Lauber K
    Oncotarget; 2016 Jul; 7(28):43199-43219. PubMed ID: 27259245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
    He S; Smith DL; Sequeira M; Sang J; Bates RC; Proia DA
    Invest New Drugs; 2014 Aug; 32(4):577-86. PubMed ID: 24682747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach.
    Spiegelberg D; Abramenkovs A; Mortensen ACL; Lundsten S; Nestor M; Stenerlöw B
    Sci Rep; 2020 Apr; 10(1):5923. PubMed ID: 32246062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron-oxide nanoparticles target intracellular HSP90 to induce tumor radio-sensitization.
    Shetake NG; Kumar A; Pandey BN
    Biochim Biophys Acta Gen Subj; 2019 May; 1863(5):857-869. PubMed ID: 30794824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
    Wang Y; Liu H; Diao L; Potter A; Zhang J; Qiao Y; Wang J; Proia DA; Tailor R; Komaki R; Lin SH
    Clin Cancer Res; 2016 Dec; 22(23):5876-5886. PubMed ID: 27354472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.
    Hirakawa H; Fujisawa H; Masaoka A; Noguchi M; Hirayama R; Takahashi M; Fujimori A; Okayasu R
    Cancer Med; 2015 Mar; 4(3):426-36. PubMed ID: 25582113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of pochoxime prodrugs as potent HSP90 inhibitors.
    Wang C; Barluenga S; Koripelly GK; Fontaine JG; Chen R; Yu JC; Shen X; Chabala JC; Heck JV; Rubenstein A; Winssinger N
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3836-40. PubMed ID: 19410458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201.
    Huerta S; Gao X; Livingston EH; Kapur P; Sun H; Anthony T
    Surgery; 2010 Aug; 148(2):346-53. PubMed ID: 20633731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 inhibitors as promising agents for radiotherapy.
    Kabakov AE; Kudryavtsev VA; Gabai VL
    J Mol Med (Berl); 2010 Mar; 88(3):241-7. PubMed ID: 19946660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DCZ5248, a novel dual inhibitor of Hsp90 and autophagy, exerts antitumor activity against colon cancer.
    Chen XL; Liu P; Zhu WL; Lou LG
    Acta Pharmacol Sin; 2021 Jan; 42(1):132-141. PubMed ID: 32404982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
    Kabakov AE; Kudriavtsev VA; Makarova IuM
    Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
    Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
    Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts.
    Mehta RK; Pal S; Kondapi K; Sitto M; Dewar C; Devasia T; Schipper MJ; Thomas DG; Basrur V; Pai MP; Morishima Y; Osawa Y; Pratt WB; Lawrence TS; Nyati MK
    Clin Cancer Res; 2020 Oct; 26(19):5246-5257. PubMed ID: 32718999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor.
    Lim T; Lee I; Kim J; Kang WK
    Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):316-25. PubMed ID: 26277021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
    Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
    Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
    Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
    Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
    Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
    Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Hsp90 chaperone: synthesis of novel resorcylic acid macrolactone inhibitors of Hsp90.
    Day JE; Sharp SY; Rowlands MG; Aherne W; Workman P; Moody CJ
    Chemistry; 2010 Mar; 16(9):2758-63. PubMed ID: 20087915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin Radiosensitizes p53-Deficient Colorectal Cancer Cells through Induction of G2/M Arrest and Inhibition of DNA Repair Proteins.
    Jeong YK; Kim MS; Lee JY; Kim EH; Ha H
    PLoS One; 2015; 10(11):e0143596. PubMed ID: 26599019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.